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Abstract As part of its single technology appraisal
(STA) process, the National Institute for Health and Care
Excellence (NICE) invited the manufacturer of rituximab
(Roche Products) to submit evidence of the clinical and
cost effectiveness of rituximab in combination with cor-
ticosteroids for treatment of anti-neutrophil cytoplasmic
antibody (ANCA)-associated vasculitis (AAV). The
School of Health and Related Research Technology
Appraisal Group at the University of Sheffield was
commissioned to act as the independent Evidence Review
Group (ERG). The ERG produced a critical review of the
evidence for the clinical and cost effectiveness of the
technology, based upon the manufacturer’s submission to
NICE. The evidence was derived mainly from a double-
blind, phase III, placebo-controlled trial of rituximab in
patients with new or relapsed ‘severe’ AAV, which
compared a rituximab treatment regimen with an oral
cyclophosphamide treatment regimen. Intravenous cyclo-
phosphamide is also commonly used but was not included
in the pivotal trial. The evidence showed that rituximab is
noninferior to oral cyclophosphamide in terms of induc-
tion of remission in adults with AAV and de novo dis-
ease, and is superior to oral cyclophosphamide in terms of
remission in adults who have relapsed once on cyclo-
phosphamide. The ERG concluded that the results of the
manufacturer’s economic evaluation could not be con-
sidered robust, because of errors and because the full
range of relevant treatment sequences were not modelled.
The ERG amended the manufacturer’s model and dem-
onstrated that rituximab was likely to represent a cost-
effective addition to the treatment sequence if given after
cyclophosphamide treatment.
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Rituximab given at a dose of 4 9 375 mg/m2 has an
effectiveness profile similar to that of oral
cyclophosphamide in terms of induction of remission
in adults with anti-neutrophil cytoplasmic antibody-
associated vasculitis and de novo disease, and it
appears to be more effective than oral
cyclophosphamide in terms of inducing remission in
adults who have relapsed once on cyclophosphamide
Rituximab appears to represent a cost-effective
addition to the treatment sequence at a cost-
effectiveness threshold of £20,000 per quality-
adjusted life-year gained, provided it is received only
by patients who have exhausted their use of
cyclophosphamide
The National Institute for Health and Care
Excellence (NICE) Appraisal Committee
recommended rituximab within its licensed
indication. However, the recommendation was not as
first-line treatment, except in patients who could not
have cyclophosphamide
The evidence was restricted to adults with
generalized, ‘severe’ anti-neutrophil cytoplasmic
antibody-associated vasculitis, and longer-term data
on safety are required
1 Introduction
Health technologies must be shown to be clinically effec-
tive and to represent a cost-effective use of National Health
Service (NHS) resources to be recommended for use within
the NHS in England and Wales. The National Institute for
Health and Care Excellence (NICE) is an independent
organization responsible for providing national guidance
on promoting good health and preventing and treating ill
health in priority areas with significant impact. The NICE
single technology appraisal (STA) process usually covers
new technologies soon after they have received UK mar-
keting authorization and is specifically designed for
appraisal of a single health technology within a single
indication [1]. Within the STA process, the manufacturer
provides NICE with a written submission, alongside a
mathematical model that summarizes the manufacturer’s
estimates of the clinical and cost effectiveness of the
technology. This submission is reviewed by the Evidence
Review Group (ERG), an external academic organization
independent of NICE, with advice from clinical specialists,
and an ERG report is produced. After consideration of the
manufacturer’s submission, the ERG report and testimony
from experts and other stakeholders, the NICE Appraisal
Committee formulates the preliminary guidance, the
appraisal consultation document (ACD), which indicates
the initial decision of the Appraisal Committee regarding
the recommendation (or not) of the intervention. Stake-
holders are then invited to comment on the submitted
evidence and the ACD, after which a subsequent ACD may
be produced or a final appraisal determination (FAD) is
issued, which is open to appeal. An ACD is not produced
when the intervention is recommended without restriction;
in that instance, a FAD is produced directly.
This paper presents a summary of the ERG report [2] for
the STA of rituximab (RTX) in combination with corti-
costeroids for the treatment of anti-neutrophil cytoplasmic
antibody (ANCA)-associated vasculitis (AAV), and the
subsequent development of the NICE guidance for the use
of this drug in England and Wales. This is one in a series of
STA summaries [3–25] being published in Pharmaco-
Economics. Full details of all relevant appraisal documents
(including the appraisal scope, ERG report, manufacturer
and consultee submissions, FAD and comments from
consultees) can be found on the NICE website [26].
2 The Decision Problem
RTX in combination with glucocorticoids is licensed for
induction of remission in adults with severe, active gran-
ulomatosis with polyangiitis (GPA, also known as We-
gener’s granulomatosis [WG]) and microscopic
polyangiitis (MPA). GPA and MPA are the two major
forms of AAV, a multisystem disorder characterized by
inflammation and necrosis of small blood vessels and
medium arteries [27]. GPA and MPA have comparable
clinical features: left untreated, the natural history is that of
a rapidly progressive, usually fatal disease [27]. In early
studies of GPA, a mean survival of 5 months was observed,
with 82 % of patients dying within 1 year [28].
AAV can manifest in many different ways, and patients
may report different symptoms over time [29]. Common
symptoms are often flu-like and include ear, nose and
throat problems, such as hearing loss, otalgia, rhinorrhoea,
otorrhoea, sinusitis, nasal crusting and recurrent otitis
media [29]. The lungs and kidneys are often affected, as are
the eyes and the nervous system [29]. Without treatment,
AAV may rapidly lead to multiple organ failure and death,
mainly caused by progressive renal failure and respiratory
failure [28, 29]. However, modern treatment has signifi-
cantly improved the prognosis of patients with AAV, and
the disease is now typically chronic, with relapsing and
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remitting phases. Despite this, the mortality rates remain
approximately 2.6 times higher than those of an age-mat-
ched population [30]. The precise aetiology of AAV is
unknown.
Disease onset usually occurs at 65–74 years of age,
although it can occur at any age [31]. The combined
average annual incidence of GPA and MPA in Norfolk,
UK, between 1988 and 2010 was 17.2 per million people,
and the prevalence at the end of 2008 was estimated to be
209 per million people [32]. The prevalence is generally
higher in men, but the disease more commonly develops at
a younger age in women [33].
It is important to note that RTX in combination with
glucocorticoids is licensed for use in patients with severe
GPA and MPA. In the manufacturer’s submission, it was
estimated that one third of patients have severe disease, but
the definition of severity is not clear cut. The European
Vasculitis Study Group and British Society for Rheuma-
tology guidelines categorize severe AAV as disease
including renal or other vital organ failure, with a serum
creatinine level of greater than 500 lmol/L (5.6 mg/dL)
[27, 34]. However, the pivotal trial of RTX in combination
with glucocorticoids, the Rituximab in ANCA-Associated
Vasculitis (RAVE) trial, excluded patients with severe
disease who required mechanical ventilation because of
alveolar haemorrhage and patients with a serum creatinine
level of greater than 4.0 mg/dL attributed to underlying
AAV disease [35]. Under these guidelines, the RAVE
definition of severe disease appears closer to what is clas-
sified as ‘generalized’ disease, where vital organ function is
threatened and the serum creatinine level is less than
500 lmol/L (5.6 mg/dL). Because patients with a serum
creatinine level of greater than 500 lmol/L were excluded
from the RAVE trial, conclusions could not be reached
regarding the effectiveness of RTX in that group. The ERG
referred to the population included in the RAVE trial as
those with generalized, ‘severe’ disease but recognized that
according to other definitions, this population may be
classed as having generalized disease, and that patients with
the most severe disease were excluded from this definition.
2.1 Current Treatment
Cyclophosphamide (CYC) in combination with glucocor-
ticoids (usually prednisolone) represents the mainstay of
remission induction treatment for generalized and severe
AAV [34]. There is currently no universal agreement as to
whether treatment should be with oral CYC (2 mg/kg per
day, for up to 6 months) or intravenous pulses following
the CYCLOPS regimen (15 mg/kg every 2 weeks for three
pulses, followed by the same dose administered at 3-week
intervals, for up to 6 months). Typically, treatment with
intravenous pulses is thought to lead to a lower risk of side
effects but may lead to a higher risk of relapse [34]. While
CYC represents the standard of care for patients with
moderate or severe AAV, other treatments, such as my-
cophenolate mofetil or methotrexate, may be used in
patients who are intolerant of CYC or who do not wish to
receive it. Those treatments have been investigated in
generally less severely affected AAV patients [36, 37], and
their effectiveness in patients with severe AAV is
unknown.
Once patients have been induced into remission, they
generally receive remission maintenance therapy with a
combination of low-dose glucocorticoid therapy and aza-
thioprine (2 mg/kg per day for at least 24 months) [34].
Leflunomide (20–30 mg per day) or methotrexate
(20–25 mg/kg per week) are also sometimes used for
remission maintenance [34].
The introduction of CYC treatment in the 1970s resulted
in a significant reduction in mortality associated with the
disease. However, considerable morbidity associated with
both the disease and the treatment remains. In patients who
are successfully induced into remission, up to 50 % will
relapse within 5 years, and each relapse carries a risk of
subsequent critical organ damage [27, 28]. Therapies used
to treat AAV are themselves also associated with sub-
stantial toxicities, which frequently result in severe and
permanent patient morbidity and mortality [38]. In partic-
ular, treating AAV with CYC can lead to opportunistic
infections, bone marrow suppression, hemorrhagic cystitis,
infertility and cancer—particularly haematopoietic and
bladder malignancies [39, 40]. There are also substantial
morbidities associated with a repeated and prolonged
course of glucocorticoids. Infections are a well-known
complication of glucocorticoids, especially in the treatment
of vasculitis [41]. Other known complications of steroid
therapy include new-onset diabetes, osteoporosis, avascular
necrosis, peptic ulcers and cataracts [42].
RTX, a genetically engineered chimeric mouse/human
monoclonal antibody, received a positive opinion from the
European Medicines Agency’s Committee for Medicinal
Products for Human Use in March 2013 for the indications
of GPA and MPA [43]. The indicated RTX dose is 375 mg/
m2, administered as an intravenous infusion once per week
for 4 weeks, although a 2 9 1,000 mg dose administered
on day 1 and day 15 of the treatment cycle is widely used
off-label in the UK for AAV. RTX should be combined
with glucocorticoid treatment [44].
NICE issued a final scope to appraise the clinical
effectiveness and cost effectiveness of RTX for treatment
of patients with AAV. The decision problem addressed in
the manufacturer’s submission differed slightly from the
NICE scope, because of the slightly more restrictive nature
of the drug’s indication. The appraisal considered treatment
with RTX in combination with corticosteroids for
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induction of remission in patients with severe AAV (MPA
or GPA), compared with alternative treatment strategies.
The outcome measures that were included were mortality,
the remission rate and the duration of remission, relapse
rates, the cumulative dose of immunosuppressants, adverse
events (AEs) and health-related quality of life (HRQoL).
An economic evaluation expressing the cost effectiveness
of RTX in terms of an incremental cost per quality-adjusted
life-year (QALY) gained was submitted to NICE by the
manufacturer.
3 The Independent Evidence Review Group Review
The ERG report comprised a critical review of the clinical
and cost-effectiveness evidence presented in the manufac-
turer’s submission, assessing the appropriateness of the
manufacturer’s interpretation and analysis of the evidence.
In accordance with the process for STAs, the ERG had
the opportunity to seek clarification on specific points in
the manufacturer’s submission, which resulted in the
manufacturer providing additional information. The ERG
also modified the manufacturer’s model to examine the
impact of altering certain key assumptions on the model
results.
3.1 Clinical Evidence Provided By the Manufacturer
The clinical effectiveness evidence in the submission was
based predominantly on data from two randomized, con-
trolled trials. RAVE was a multicentre, randomized, pla-
cebo-controlled, double-blind, double-dummy,
noninferiority trial, which compared RTX (375 mg/m2 per
week for 4 weeks) and CYC (2 mg/kg per day) for induction
of remission in 197 patients with new or relapsed severe
MPA or GPA [35]. The Randomized Trial of Rituximab
Fig. 1 Manufacturer’s model structure (drawn by the Evidence Review Group). AZA azathioprine, CYC cyclophosphamide, RTX rituximab
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Versus Cyclophosphamide in ANCA-Associated Vasculitis
(RITUXVAS) was a phase II, open-label, randomized,
controlled, prospective study, which evaluated RTX
(375 mg/m2 per week for 4 weeks) combined with two
intravenous doses of CYC (15 mg/kg given with the first and
third RTX doses), compared with the CYCLOPS intrave-
nous CYC regimen (15 mg/kg for 3–6 months, 6–10 doses in
total) in 44 patients with newly diagnosed severe AAV [45].
In both studies, patients in the CYC control group received
azathioprine as remission maintenance therapy, whereas
patients in the RTX group received no remission mainte-
nance therapy. The manufacturer gave precedence to data
from the RAVE trial because this reflected the regimen
sanctioned in the market authorization, presenting data from
RITUXVAS as supporting evidence.
In RAVE, the primary endpoint was remission of dis-
ease without use of prednisone at 6 months; glucocorti-
coids were tapered off, such that all patients who had
remission without disease flares had discontinued gluco-
corticoids by 5 months. Remission was signified by a
Birmingham Vasculitis Activity Score for WG (BVAS/
WG) [46] of 0. Secondary endpoints included the rates of
disease flares, a BVAS/WG of 0 with less than 10 mg per
day of prednisone use, the cumulative glucocorticoid dose,
rates of AEs, and HRQoL measured using the Medical
Outcomes Study 36-Item Short-Form Health Survey (SF-
36) [47]. A disease flare was defined as an increase in the
BVAS/WG of C1 point.
The manufacturer reported the results of the RAVE trial,
which are published elsewhere [35]. The trial demonstrated
noninferiority of RTX compared with CYC because the
lower bound of the 95 % confidence interval for the pri-
mary endpoint was higher than the pre-determined nonin-
feriority margin of -20% (p \ 0.001). Sixty-three patients
(63.6 %) in the RTX group achieved complete remission,
compared with 52 patients (53.1 %) in the CYC group, an
absolute difference of 10.6 % (95 % confidence interval
[CI] -3.2 to 24.3 %, p = 0.132), hence a statistically
significant advantage associated with RTX was not
observed. Statistically significant changes in the secondary
efficacy endpoints measured in RAVE were not observed,
other than in exploratory subgroup analyses [35]. Explor-
atory subgroup analysis of complete remission in newly
diagnosed patients gave an absolute difference of -4.2 %
(95 % CI -23.6 to 15.3 %, p = 0.673) in favour of CYC
(60.4 % in the RTX group compared with 64.6% in the
CYC group). A similar analysis in patients with recurrent
disease gave a statistically significant absolute difference
of 24.7 % (95 % CI 5.8 to 43.6 %, p = 0.013) in favour of
RTX (66.7 % in the RTX group compared with 42.0 % in
the CYC group).
In RITUXVAS, the primary endpoints were sustained
remission (defined as an absence of disease activity
[BVAS = 0] for at least 6 months) and the rates of severe
AEs at 12 months. Sustained remission occurred in 25 of
33 patients in the RTX group (76 %) and in 9 of 11 patients
in the control group (82 %). The absolute difference in
sustained remission with RTX as compared with CYC was
-6 percentage points (95 % CI -33 to 21, p = 0.68).
Among the patients who remained alive at 12 months,
93 % of the patients in the RTX group and 90 % of those in
the control group had sustained remission (p = 0.80).
There were no significant differences between the treat-
ment arms for any of the secondary efficacy outcomes,
such as the median time to remission, the median BVAS
and the prednisone doses.
The manufacturer submitted evidence on the safety of
RTX, focussed on 18 months of data collected in RAVE.
There were no reported significant differences between the
treatment groups in almost all AE outcomes, but there were
some notable disparities regarding leucopenia and malig-
nancies. More patients in the CYC group than in the RTX
group (32 [33 %] versus 22 [22 %], p = 0.01) had one or
more of the predefined selected AEs (including death,
malignant conditions, grade 2 or higher leucopenia or
thrombocytopenia, grade 3 or higher infections, drug-
induced cystitis, venous thromboembolic events, stroke,
hospitalizations and infusion reactions that contraindicated
further infusions), but more episodes of grade 2 or higher
leucopenia in the control group (10 versus 3) accounted for
most of this difference. Malignant conditions developed in
7 patients after 6 months: 6 of 124 patients (5 %) who were
exposed to RTX at any point during the trial (including
after 6 months), as compared with 1 of 73 patients (1 %)
without exposure to RTX (p = 0.26).
The manufacturer presented limited safety results from
the RITUXVAS trial, but the ERG noted that a total of 31
severe AEs had occurred in 14 of the 33 patients in the RTX
group (42 %), and 12 severe AEs had occurred in 4 of the 11
patients in the control group (36 %). The incidence rates of
severe AEs did not differ significantly between the groups
(p = 0.77). Six of the 33 patients in the RTX group (18 %)
and 2 of the 11 patients in the control group (18 %) died
(p = 1.00). The causes of death were infections (in 3 patients
in the RTX group and in 1 patient in the control group),
cardiovascular disease (in 1 patient in the RTX group and in 1
patient in the control group), and complications of end-stage
renal failure (in 2 patients in the RTX group).
3.1.1 Critique of Clinical Evidence and Interpretation
The ERG noted that the manufacturer identified the two
randomized, controlled trials comparing RTX with CYC as
induction therapy for adults with what can be described as
generalized, severe AAV. The manufacturer did not con-
duct a meta-analysis or synthesis, and thus the results were
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reported as they were in the relevant published studies. The
ERG considered that evidence from RAVE suggests that
RTX given at a dose of 4 9 375 mg/m2 is noninferior to
oral CYC in terms of induction of remission in adults with
AAV and de novo disease, and is superior to oral CYC in
terms of remission in adults with generalized, severe AAV
who have relapsed one time on CYC, on the basis of the
exploratory subgroup analysis. Evidence from RITUXVAS
suggests that RTX given at a dose of 4 9 375 mg/m2 plus
2–3 intravenous pulses of CYC is noninferior to intrave-
nous pulse CYC in terms of remission in adults with
generalized, severe AAV and de novo disease. The ERG
stated that the evidence relates only to induction of
remission with these specific regimens in adult populations
with generalized, severe AAV, and only evidence on the
4 9 375 mg/m2 RTX dose was submitted by the manufac-
turer, rather than the 2 9 1 mg dose, which the manufacturer
recognized as the most widely used off-label dose in the UK
for AAV, and which represents a smaller overall dose. No
evidence was presented on the efficacy or safety of RTX in
adults intolerant of CYC, with contraindications against
CYC or with mild AAV; in children; or for use of this regi-
men as maintenance therapy or for relapse after RTX.
The ERG applied the Cochrane risk-of-bias tool to
appraise the RAVE and RITUXVAS trials [48], as well as
the noninferiority trial extension of the CONSORT state-
ment for the RAVE trial [49]. In general, both trials were
considered to be at low risk of bias, although there was a
high risk of performance and detection bias in the RIT-
UXVAS trial because of its open-label nature. In addition,
the ERG had concerns over the populations, interventions,
comparators and outcomes included in the studies, with
regard to their usefulness for informing UK recommenda-
tions. The RAVE trial considered relatively young adults
only (the mean ages were 54 and 51 years in the RTX and
CYC treatment arms, respectively) with moderately severe
AAV and either de novo disease or following relapse after
CYC. The trial did not include adults with severe renal
impairment or life-threatening pulmonary haemorrhage,
those who had contraindications against CYC or those who
were CYC refractory. It is uncertain if RTX alone will
demonstrate equal efficacy and safety in other adult pop-
ulations or children. The RITUXVAS trial considered a
much older population (with median ages of 68 and
67 years in the RTX and control treatment arms, respec-
tively) with severe renal impairment, but both arms of the
trial included CYC treatment. In the absence of a head-to-
head trial, it is uncertain whether RTX combined with
CYC is inferior, equivalent or superior to RTX alone.
The ERG noted that the manufacturer’s submission
focused upon oral CYC as a comparator. It is uncertain
whether RTX without CYC would demonstrate equal
efficacy and safety if it were compared with intravenous
CYC. The ERG received clinical expert advice that intra-
venous CYC is used more often in expert clinical practice,
and this might have a better safety profile [50, 51]. In
addition, the ERG noted that no evidence was submitted on
the comparability of RTX with other potentially relevant
comparators specified in the NICE scope, such as myco-
phenolate mofetil and methotrexate. The ERG noted that
some evidence on these interventions—such as the
NORAM trial [36, 52] and the MYCYC trial [37]—is
available, which could have informed an indirect compar-
ison; however, the manufacturer’s submission did not
contain such an analysis.
The ERG considered the lack of longer-term data on
efficacy and safety to be a significant concern. RAVE and
RITUXVAS did not monitor outcomes beyond 18 months,
and primary endpoints were measured at 6 and 12 months,
respectively. The duration of remission was not reported as
an outcome in either trial, yet it has important implications
from both a clinical perspective and an economic per-
spective. Regarding safety, RAVE provided evidence that
RTX with concurrent glucocorticoid therapy has a safety
profile similar to that of oral CYC with concurrent gluco-
corticoid therapy, and the RITUXVAS trial suggested that
RTX plus intravenous pulse CYC with concurrent gluco-
corticoid therapy has a safety profile similar to that of
intravenous pulse CYC with concurrent glucocorticoid
therapy. However, the safety data were collected over
relatively short time periods (maximum 18 months), and
much of the observed toxicity was related to steroids rather
than to RTX or CYC. Thus it is not possible to draw
conclusions specifically comparing the safety of RTX and
CYC. In addition, part of the hypothesis for the RITUX-
VAS trial was the potential for improved safety through
treatment with RTX rather than CYC. This was not dem-
onstrated in RAVE or RITUXVAS. One reason suggested
for the comparable rather than superior safety profile of
RTX in the RITUXVAS and RAVE trials relates to the
short durations of these trials [35]. A further reason might
be that the high cumulative dose of RTX in both trials [53–
55] caused AEs. The ERG concluded that longer-duration
trials with more comparable groups are needed—particu-
larly to assess malignancies and fertility outcomes—and
patients who have previously received CYC need to be
included in such trials.
3.2 Cost-Effectiveness Evidence
The manufacturer conducted a systematic review on the
cost effectiveness of one or more interventions for patients
with AAV. No suitable studies were found, and the man-
ufacturer therefore submitted a de novo model-based eco-
nomic evaluation, which assessed the cost effectiveness of
different treatment strategies for patients with AAV.
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Separate analyses were undertaken for patients with newly
diagnosed AAV, people with recurrent AAV, all patients
(including both newly diagnosed and relapsed patients) and
patients intolerant of CYC. The model was constructed
using a cohort Markov approach with a 6-month cycle
length. Patients entered the model at an age of 52.8 years,
based upon the mean age at baseline in the RAVE trial. A
lifetime time horizon was modelled. Health states were
included for remission, non-remission, uncontrolled dis-
ease and death (Fig. 1). The structure of the model is
outlined in the ERG report [2].
Model parameter values for response rates were primarily
taken from the RAVE trial. However, the model incorpo-
rated various treatment sequences, including two courses of
CYC and RTX for selected patients, and for some sequences,
data were not available from RAVE, and so assumptions
were made. For each subgroup that was modelled, the rele-
vant response rate was taken from RAVE where possible—
RAVE provided data on response rates for CYC and RTX in
the treatment-naı̈ve subgroup, the recurrent-disease sub-
group and all patients. For the recurrent-disease subgroup, no
data on remission rates associated with a second course of
CYC could be derived from the RAVE trial, and no data were
available on the remission rates associated with a second
course of RTX. The manufacturer assumed reduced response
rates for these parameters.
The relapse rates used in the manufacturer’s model were
derived from the RAVE trial. Exponential models were fitted
to flare data from patients who had experienced remission at
6 months, in order to estimate the time-to-event for relapse.
The same relapse rate was applied after different courses of
treatment within each subgroup analysis, but different
relapse rates were used in each subgroup.
Age- and sex-specific mortality risks were based upon
UK life tables [56], adjusted according to the age and
gender distributions in the RAVE trial and a published
standardized mortality ratio (SMR) comparing a general
population with an AAV population [57]. The AAV SMR
was applied directly to the non-remission health state, and
the SMR was arbitrarily altered by ±10 % to reflect mor-
tality in the remission and uncontrolled-disease states.
Utility scores were based upon UK evidence for the
general population [58], adjusted according to the RAVE
trial demographics and weighted for remission
(weight = 0.98) and non-remission (weight = 0.88) health
states, according to SF-36 data (subsequently transformed
into EQ-5D utility scores) collected from the RAVE trial.
An additional utility decrement was applied to patients in
the uncontrolled-disease health state (weight = 0.79),
assuming that the difference between the non-remission
and uncontrolled-disease health states is the same as the
difference between the remission and non-remission health
states. Further decrements were made according to the
probability of experiencing AEs in each health state. The
AE rates were based upon data from RAVE and included
anaemia, leucopenia, deep vein thrombosis, dyspnoea,
diarrhoea and pneumonia. The costs of managing these
AEs were based upon relevant costs taken from the NHS
Trusts reference costs schedules for 2009–2010 [59].
Drug acquisition costs were taken from British National
Formulary No. 64 [60] and were based upon licensed
doses, apart from glucocorticoid costs, which were based
upon the average dose used in the RAVE trial. Adminis-
tration costs for RTX and intravenous CYC were assumed
to be equal and were based upon a previous economic
evaluation of infliximab [61]. Monitoring costs were
included for oral CYC and for patients receiving azathio-
prine maintenance therapy. Regular outpatient appoint-
ments with relevant consultant specialists were also
assumed, the frequency of which differed across health
states—notably, once patients were in the uncontrolled-
disease health state, it was assumed that they attended one
specialist palliative care outpatient appointment every
1.5 weeks for all remaining years of life. The costs of these
appointments were valued using NHS reference costs.
The results from the manufacturer’s base-case analysis
are shown in Table 1. These results represent those pro-
vided by the manufacturer after it responded to clarifica-
tions requested by the ERG, as some amendments were
made to the economic model. They indicate that the RTX
treatment strategy results in an incremental cost-effective-
ness ratio (ICER) of £8,544 per QALY gained for all
patients, but in the treatment-naı̈ve and recurrent-disease
subgroups, the ICERs were £55,175 per QALY gained and
£43,003 per QALY gained, respectively. In the CYC-
intolerant subgroup analysis, RTX dominated the compar-
ator, which was deemed to represent best supportive care.
The manufacturer undertook probabilistic sensitivity ana-
lysis but did not report the probabilistic ICERs. For the all-
patients analysis, the manufacturer reported that the prob-
abilities of the RTX treatment sequence being cost effec-
tive, compared with the CYC treatment sequence, were
61.7 % and 64.6 % for cost-effectiveness thresholds of
£20,000 and £30,000 per QALY gained, respectively. The
manufacturer presented several deterministic sensitivity
analyses and found that the results of the all-patients ana-
lysis were relatively insensitive to variations in the tested
model input parameters, with the exception of (i) the CYC
remission rate; (ii) the uncontrolled-disease utility; (iii) the
frequency of consultant visits in each health state; and
(iv) the reference cost applied to the consultant appoint-
ments in the uncontrolled-disease health state. In addition,
several structural sensitivity analyses were presented, test-
ing different numbers of CYC and RTX courses for dif-
ferent patient groups. As would be expected, the results
were highly sensitive to these structural assumptions.
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3.2.1 Critique of the Cost-Effectiveness Evidence
and Interpretation
The ERG had serious concerns with the manufacturer’s
economic model. These included technical errors, such as
minor mistakes in the estimation of mortality rates, some
inaccuracies in the estimation of standard errors for relapse
rates and cost parameters, and a failure to characterize
uncertainty around all uncertain parameters. In addition,
some parameter value estimates were inappropriate, and
some structural assumptions were implausible [2]. The
ERG took the view that the manufacturer’s economic
model could not be considered reliable or robust.
The most important issues highlighted by the ERG
surrounded the treatment sequences modelled by the
manufacturer, and the definition of the uncontrolled-dis-
ease health state. Clinical advice received by the ERG
suggested that a lifetime cumulative dose of 20–30 g of
CYC should not be exceeded. Typically, this represents
1–2 courses of oral CYC or 2–3 courses of intravenous
CYC. Hence, the treatment sequence that was modelled
should reflect the treatment history of the patient, and thus
it should differ for the different subgroups that were
modelled. For treatment-naı̈ve patients, the ERG suggested
that two courses of CYC were plausible, whereas for
patients with recurrent disease, only one course of CYC
was likely to be plausible. In addition, the manufacturer
considered treatment sequences only in which RTX was
given first-line; the ERG stated that there was no reason to
assume that this should be the case—it was relevant to
consider its cost effectiveness when it was given both
before and after CYC. Finally, the ERG disagreed with the
manufacturer’s assumption that patients who did not
respond to an initial course of RTX would immediately
receive a second course of RTX—the ERG believed it was
more appropriate to include only one course of RTX within
the modelled treatment sequences.
The ERG’s clinical advisors suggested that the uncon-
trolled-disease health state modelled by the manufacturer
was unrealistic, and that a more common health state is one
in which the most effective induction treatments have been
used but some other treatment or combination of treatments
is utilized in order to afford patients a reasonable level of
disease control. This may be described as low-grade
‘grumbling’ disease [62]. The ERG noted that the level of
HRQoL associated with such a health state was unlikely to
be substantially worse than that experienced in the non-
remission health state. Also, although treatment would be
received in this state, the manufacturer’s assumption that
specialist palliative care is received at hospital outpatient
appointments once every 1.5 weeks for all remaining years
of life appeared to be a substantial overestimate. The
ERG’s clinical advisors suggested it would be more
appropriate to assume that patients in this health state
would continue to receive maintenance treatment, and that
outpatient appointments would occur each month initially,
followed by less frequent visits over time. In the base-case
version of the manufacturer’s model, patients in the CYC
group spent 70.7 % of their mean life expectancy in the
uncontrolled-disease health state, compared with 63.2 % in
the RTX group. The cost savings and utility benefits
associated with RTX due to this were likely to be sub-
stantially overestimated.
3.3 Additional Work Undertaken By the Evidence
Review Group
The ERG amended the identified technical errors in the
manufacturer’s model, amended several parameter value
estimates to better reflect reality (particularly for the
Table 1 Headline cost-effectiveness results presented by the manufacturer
Option QALYs Cost Incremental QALYs Incremental cost Incremental cost per QALY gained
All patients
CYC 8.03 £95,819 – – –
RTX 8.19 £97,210 0.1628 £1,391 £8,543.69
Treatment-naı̈ve subgroup
CYC 8.45 £81,327 – – –
RTX 8.53 £86,021 0.0851 £4,694 £55,174.92
Recurrent-disease subgroup
CYC 7.89 £100,699 – – –
RTX 7.98 £104,550 0.0896 £3,851 £43,003.05
CYC–intolerant subgroup
BSC 7.49 £102,721 – – –
RTX 8.02 £97,836 0.5386 -£4,885 RTX dominates
BSC best supportive care, CYC cyclophosphamide, QALY quality-adjusted life-year, RTX rituximab
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uncontrolled-disease health state) and amended the mod-
elled treatment sequences to allow for fully incremental
analyses of introducing RTX into the treatment sequence
either before or after CYC. The cost-effectiveness results
for all patients and for the treatment-naı̈ve, recurrent-dis-
ease and CYC-intolerant subgroups are shown in Table 2.
The additional work undertaken by the ERG indicated
that including RTX in the treatment sequence increases
health benefits, compared with the current standard treat-
ment sequence (that is, a treatment sequence that does not
include RTX). In the analyses for all patients, the treat-
ment-naı̈ve subgroup and the recurrent-disease subgroup
(for patients who are eligible for further CYC treatment),
the ICER associated with adding RTX after CYC treatment
had been exhausted was in the range of £11,129 to £12,851
per QALY gained. However, in each of these analyses, the
ICERs associated with administering RTX earlier in the
treatment sequence were greater than £50,000 per QALY
gained—sometimes substantially so. It is particularly
important to note the substantial reductions in total lifetime
costs resulting from the ERG’s amended model, compared
with the manufacturer’s original model (the manufacturer
estimated lifetime costs in the region of £100,000 per
patient, compared with the ERG’s estimates of around
£20,000). This is almost entirely due to the apparent sub-
stantial overestimation of costs associated with the
uncontrolled-disease health state in the manufacturer’s
original model.
In the recurrent-disease subgroup (for patients who are
ineligible for further CYC treatment) and in the CYC-
intolerant subgroup, the ICER associated with treating
patients with RTX rather than best supportive care was in
the range of £10,699 to £11,277 per QALY gained. In these
scenarios (and in all other scenarios), best supportive care
represents continued treatment to maintain patients in a
state of low-grade ‘grumbling’ disease. The ERG noted
that while these analyses were useful, they were limited
and may represent underestimates of the true ICER because
relevant comparators such as mycophenolate mofetil were
not included in the model.
3.4 Conclusions of the Evidence Review Group Report
On the basis of the clinical evidence provided in the
manufacturer’s submission, RTX given at a dose of
4 9 375 mg/m2 has an effectiveness and safety profile
similar to that of oral CYC in terms of induction of
remission in adults with AAV and de novo disease. For
patients who have relapsed once on CYC, RTX appears to
be more effective than oral CYC in terms of inducing
remission in adults with generalized, severe AAV. How-
ever, the submitted evidence was limited because it
Table 2 Cost-effectiveness results of the Evidence Review Group’s preferred analyses
Strategy Total cost Total QALYs Incremental QALYs Incremental cost ICER
All patients
CYC ? CYC ? BSC £18,926.57 8.5810 – – –
CYC ? CYC ? RTX ? BSC £22,820.93 8.9035 0.32 £3,894.36 £12,075.42
CYC ? RTX ? CYC ? BSC £23,176.00 8.9086 0.0051 £355.07 £69,709.63
RTX ? CYC ? CYC ? BSC £23,755.25 8.9131 0.0045 £579.25 £127,456.12
Treatment-naı̈ve subgroup
CYC ? CYC ? BSC £18,645.81 8.6491 – – –
CYC ? CYC ? RTX ? BSC £22,429.08 8.9435 0.29 £3,783.27 £12,850.76
CYC ? RTX ? CYC ? BSC £22,793.54 8.9480 0.0045 £364.46 £81,603.50
RTX ? CYC ? CYC ? BSC £23,636.83 8.9507 0.0027 £843.29 £317,037.96
Recurrent-disease subgroup (eligible for additional CYC treatment)
CYC ? BSC £17,593.48 8.2548 – – –
CYC ? RTX ? BSC £22,295.52 8.6773 0.4225 £4,702.04 £11,129.22
RTX ? CYC ? BSC £22,620.65 8.6836 0.0063 £325.14 £51,841.87
Recurrent-disease subgroup (ineligible for additional CYC treatment)
BSC £15,747.48 7.9379 – – –
RTX ? BSC £21,132.39 8.4412 0.5033 £5,384.90 £10,699.45
CYC-intolerant subgroup
BSC £15,747.48 7.9379 – – –
RTX ? BSC £21,184.13 8.4200 0.48 £5,436.64 £11,277.29
BSC best supportive care, CYC cyclophosphamide, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, RTX rituximab
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included only one trial that incorporated the licensed reg-
imen, and it did not include evidence on long-term safety
and effectiveness.
The ERG could not offer robust estimates of the likely
cost effectiveness of RTX based upon the original version
of the manufacturer’s economic model. Several amend-
ments had to be made. On the basis of the ERG’s amended
version of the manufacturer’s economic model, RTX
appeared to represent a cost-effective addition to the
treatment sequence at a cost-effectiveness threshold of
£20,000 per QALY gained, provided it was received only
by patients who had exhausted their use of CYC.
4 Key Methodological Issues
Several important methodological issues were highlighted
during the appraisal. The manufacturer made implausible
assumptions regarding the resource use associated with
different health states included in the model, and did not
model all relevant treatment sequences. In addition, the
ERG questioned the methodological approach taken by the
manufacturer to estimate relapse rates: the manufacturer
used summary data from the RAVE trial to fit an expo-
nential model to represent the time to relapse in the RTX
and CYC groups, implying an assumption that the relapse
rate was constant over time. Proportional hazards were
assumed even though Kaplan–Meier curves for the two
treatment groups crossed, alternative parametric models
(such as Weibull, Gompertz, log-normal, log-logistic,
generalized gamma) were not considered, and the use of
summary data rather than patient-level data precluded the
use of model fit statistics such as Akaike’s information
criterion and the Bayesian information criterion. Also, the
ERG suggested that the economic model could have been
made more appropriate through inclusion of an additional
health state for patients who experience a partial response
to treatment.
The methodological issues that had the largest impacts
on the results and interpretation of the economic evaluation
concerned the modelling of the disease and treatment
pathway for patients with AAV. The manufacturer did not
consider scenarios in which RTX could be given after CYC
in the treatment pathway; this substantially affected the
cost-effectiveness results. This reflects the importance of
incorporating all relevant treatment sequences in economic
evaluations where multiple lines of treatment are possible.
In addition, the manufacturer modelled a disease pathway
in which patients transited into an uncontrolled-disease
health state once they had exhausted RTX or CYC treat-
ment; this health state was characterized by low HRQoL
and very high costs. Clinical advice received by the ERG
suggested that modern treatment practices mean that in
reality, patients rarely enter such a health state—instead, a
myriad of alternative therapies can be used to maintain
higher HRQoL, at lower cost. Re-defining the uncon-
trolled-disease health state to reflect this reduced the total
costs estimated by the economic model by approximately
80 % and substantially altered the cost-effectiveness
results. This reflects the importance of ensuring that
modelled health states adequately represent the burden of
disease experienced by patients.
5 National Institute for Health and Care Excellence
Guidance
In July 2013, on the basis of the evidence available
(including verbal testimony from invited clinical experts
and patient representatives), the Appraisal Committee
recommended that NICE request further clarification from
the manufacturer, which should be made available for a
second Appraisal Committee meeting. In the meantime, the
Appraisal Committee was of a mind not to recommend
RTX for inducing remission in adults with AAV. The
requested information concerned the definition of severe
disease, longer-term effectiveness and safety data, and
information about UK clinical practice relating to the
maximum lifetime cumulative CYC dose. The Appraisal
Committee also requested that the manufacturer make
several amendments to the economic model in line with
those suggested by the ERG.
In response to this, the manufacturer provided some
additional information: no further data beyond 18 months
were available from the RAVE trial, but the manufacturer
provided information on the long-term safety of RTX when
used as a treatment for rheumatoid arthritis. The manu-
facturer clarified its definition of severe disease and—in
line with draft guidelines from the British Society of
Rheumatology—stated that the maximum lifetime cumu-
lative dose of CYC was 25 g. An updated economic model
was submitted by the manufacturer and subsequently
reviewed by the ERG.
In September 2013, the Appraisal Committee produced
preliminary advice that RTX, in combination with gluco-
corticoids, was recommended as an option for inducing
remission in adults with AAV only if further CYC treat-
ment would exceed the maximum cumulative CYC dose. A
recommendation was not made for patients intolerant of
CYC. Following further consultation, in January 2014,
NICE issued its final guidance on the use of RTX for AAV.
RTX, in combination with glucocorticoids, was recom-
mended as an option for inducing remission in adults with
AAV only if further CYC treatment would exceed the
maximum lifetime cumulative CYC dose; CYC is contra-
indicated or not tolerated; the person has not completed
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their family and treatment with CYC may materially affect
their fertility; the disease has remained active or has pro-
gressed despite a course of CYC lasting 3–6 months; or the
person has had uroepithelial malignancy [63].
5.1 Consideration of Clinical And Cost-Effectiveness
Issues
This section discusses the key issues considered by the
Appraisal Committee. The full list can be found in the
Appraisal Committee’s FAD [63].
5.1.1 Treatment Sequences
The Appraisal Committee considered the treatment
sequences included in the manufacturer’s original eco-
nomic analysis to be incomplete and unsuitable because
they did not enable fully incremental analyses for all
populations of interest. The Appraisal Committee agreed
that the treatment sequences used by the ERG in its
exploratory analysis were more comprehensive and more
appropriate. It was noted that the manufacturer’s updated
economic analysis again did not consider all relevant
treatment sequences.
The Appraisal Committee concluded that there was
uncertainty about the appropriate comparator for people
who cannot have CYC. In the original analyses undertaken
by the manufacturer and the ERG, best supportive care was
incorporated as the comparator. In response to consulta-
tion, the manufacturer provided an updated economic
analysis, which incorporated mycophenolate mofetil and
methotrexate as comparators. Clinical specialists advised
the Appraisal Committee that neither of these drugs rep-
resents a treatment of choice for people with severe dis-
ease, while the manufacturer stated that clinical specialists
whom it consulted advised that these would be used in
people who cannot have CYC. The Appraisal Committee
noted that there was substantial uncertainty around the
economic analysis presented for this subgroup of patients,
and that a comparison with mycophenolate mofetil or
methotrexate yielded an ICER of £60,600 per QALY
gained (although this fell to £26,400 per QALY gained in
the analyses provided by the ERG), whereas a comparison
with best supportive care resulted in an ICER of £11,300
per QALY gained. The Appraisal Committee concluded
that, on balance, the ICER was likely to be lower than
£30,000 per QALY gained.
5.1.2 Safety
The Appraisal Committee recognized that the risk of long-
term toxicity increases with the cumulative dose of CYC
and that this should not exceed 25 g. However, the
Appraisal Committee concluded that the safety profiles of
CYC and RTX were similar in the short term, and that
there was uncertainty about any long-term safety benefits
associated with RTX because of a lack of data from
patients with AAV.
5.1.3 The Uncontrolled-Disease Health State
The Appraisal Committee agreed that the utility value had
been underestimated and the costs had been overestimated
for the uncontrolled-disease health state in the manufac-
turer’s economic model. It was concluded that the revised
utility value applied to the uncontrolled-disease health state
was more plausible than the value in the original model but
remained a source of uncertainty.
6 Conclusion
On the basis of the evidence submitted by the manufac-
turer, the ERG concluded that RTX given at a dose of
4 9 375 mg/m2 has an effectiveness profile similar to that
of oral CYC in terms of induction of remission in adults
with AAV and de novo disease, and it appears to be more
effective than oral CYC in terms of inducing remission in
adults who have relapsed once on CYC. However, the
evidence was restricted to adults with generalized, severe
AAV, and longer-term data on safety are required. The
ERG believed that robust estimates of the likely cost
effectiveness of RTX could not be made on the basis of
the original version of the manufacturer’s economic
model. However, on the basis of the ERG’s amended
version of the manufacturer’s economic model, RTX
appeared to represent a cost-effective addition to the
treatment sequence at a cost-effectiveness threshold of
£20,000 per QALY gained, provided it was received only
by patients who had exhausted their use of CYC. The
NICE Appraisal Committee recommended RTX within its
licensed indication. However, the recommendation was
not as first-line treatment, except in patients who could
not have CYC.
Acknowledgments This project was funded by the National Insti-
tute for Health Research (NIHR) Health Technology Assessment
(HTA) Programme (project no. 12/37/01). See the HTA programme
website (http://www.hta.ac.uk) for further project information. This
summary of the ERG report was compiled after NICE issued its
guidance.
N.L. drafted the final version of the manuscript and takes respon-
sibility as the overall guarantor of the content. C.C., P.T., R.W., R.L.
and M.V. revised the manuscript for important intellectual content.
All authors have given their approval for the final version to be
published.
The views and opinions expressed herein are those of the authors
and do not necessarily reflect those of NICE or the Department of
Health.
Rituximab in Combination with Corticosteroids 1181
Conflicts of Interest N.L. undertook 1 day of consultancy for Pfizer
in 2012, providing advice on the analysis of an unrelated drug in an
unrelated disease area. Pfizer manufactures cyclophosphamide and
methotrexate (both of which are available on a nonproprietary basis).
R.L. declares that the University of Oxford received an honorarium
from Roche Oy for an academic presentation given by R.L. in 2012.
M.V. received a 1-year competitive research grant (to co-fund an
NIHR Collaborations for Leadership in Applied Health Research and
Care [CLAHRC] grant) from Roche in October 2010 and undertook
1 day of consultancy for Chemocentryx in January 2014 after this
appraisal was undertaken.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. National Institute for Health and Care Excellence. Guide to the
single technology appraisal (STA) process. 2006. 9-7-2013.
2. Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC,
Luqmani R. Rituximab in combination with corticosteroids for
the treatment of anti-neutrophil cytoplasmic antibody-associated
vasculitis: Evidence Review Group’s report. 30-5-2013. National
Institute for Health Research: Health Technology Assessment
Programme.
3. Sculpher M. Single technology appraisal at the UK National
Institute for Health and Clinical Excellence. Pharmacoeconomics.
2010;28(5):347–9.
4. Rodgers MM, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR,
et al. Alitretinoin for severe chronic hand eczema. Pharmaco-
economics. 2010;28(5):351–62.
5. Bagust A, Greenhalgh J, Boland A, Fleeman N, McLeod C,
Dickson R, et al. Cetuximab for recurrent and/or metastatic
squamous cell carcinoma of the head and neck. Pharmacoeco-
nomics. 2010;28(6):439–48.
6. Stevenson M, Pandor A. Febuxostat for the management of hy-
peruricaemia in patients with gout. Pharmacoeconomics.
2011;29(2):133–40.
7. Scotland MG, Waugh N, Royle P, McNamee P, Henderson R,
Hollick R. Denosumab for the prevention of osteoporotic frac-
tures in post-menopausal women. Pharmacoeconomics.
2011;29(11):951–61.
8. Dickson MR, Bagust A, Boland A, Blundell M, Davis H, Dundar
Y, et al. Erlotinib monotherapy for the maintenance treatment of
non-small cell lung cancer after previous platinum-containing
chemotherapy. Pharmacoeconomics. 2011;29(12):1051–62.
9. McKenna C, Maund E, Sarowar M, Fox D, Stevenson M, Pepper
C, et al. Dronedarone for the treatment of atrial fibrillation.
Pharmacoeconomics. 2012;30(1):35–46.
10. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for
the prevention of venous thromboembolism in patients under-
going elective hip or knee surgery. Pharmacoeconomics.
2012;30(2):137–46.
11. Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, et al.
Golimumab for the treatment of psoriatic arthritis. Pharmaco-
economics. 2012;30(4):257–70.
12. Boyers MD, Jia X, Jenkinson D, Mowatt G. Eltrombopag for the
treatment of chronic immune or idiopathic thrombocytopenic
purpura. Pharmacoeconomics. 2012;30(6):483–95.
13. Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K,
et al. Omalizumab for the treatment of severe persistent allergic
asthma in children aged 611 years: a NICE single technology
appraisal. Pharmacoeconomics. 2012;30(11):991–1004.
14. Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic
colorectal cancer. Pharmacoeconomics. 2012;30(12):1119–32.
15. Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S,
et al. Pazopanib for the first-line treatment of patients with
advanced and/or metastatic renal cell carcinoma. Pharmacoeco-
nomics. 2013;31(1):15–24.
16. Craig D, Rice S, Paton F, Fox D, Woolacott N. Retigabine for the
adjunctive treatment of adults with partial-onset seizures in epi-
lepsy with and without secondary generalization. Pharmacoeco-
nomics. 2013;31(2):101–10.
17. Spackman E, Rice S, Norman G, Suh DC, Eastwood A, Palmer S.
Trastuzumab for the treatment of HER2-positive metastatic gas-
tric cancer. Pharmacoeconomics. 2013;3:185–94.
18. Rafia R, Simpson E, Stevenson M, Papaioannou D. Trabectedin
for the treatment of advanced metastatic soft tissue sarcoma: a
NICE single technology appraisal. Pharmacoeconomics.
2013;6:471–8.
19. Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S,
et al. Rituximab for the first-line maintenance treatment of fol-
licular non-Hodgkin’s lymphoma. Pharmacoeconomics.
2013;5:403–13.
20. Armstrong N, Joore M, van Asselt T, Misso K, Manning N,
Tomini F, et al. Golimumab for the treatment of ankylosing
spondylitis: a NICE single technology appraisal. Pharmacoeco-
nomics. 2013;5:415–25.
21. Tosh J, Archer R, Davis S, Stevenson M, Stevens JW. Goli-
mumab for the treatment of rheumatoid arthritis after the failure
of previous disease-modifying antirheumatic drugs: a NICE sin-
gle technology appraisal. Pharmacoeconomics. 2013;8:652–61.
22. Kearns B, Jones ML, Stevenson M, Littlewood C. Cabazitaxel for
the second-line treatment of metastatic hormone-refractory
prostate cancer: a NICE single technology appraisal. Pharmaco-
economics. 2013;6:479–88.
23. Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C,
et al. Dabigatran for the prevention of stroke and systemic
embolism in atrial fibrillation: a NICE single technology
appraisal. Pharmacoeconomics. 2013;7:551–62.
24. Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N,
Reckless JPD, et al. Bivalirudin for the treatment of ST-segment
elevation myocardial infarction: a NICE single technology
appraisal. Pharmacoeconomics. 2013;4:269–75.
25. Uttley L, Kearns B, Ren S, Stevenson M. Aripiprazole for the
treatment and prevention of acute manic and mixed episodes in
bipolar I disorder in children and adolescents: a NICE single
technology appraisal. Pharmacoeconomics. 2013;31:981–90.
26. National Institute for Health and Care Excellence. Vasculitis
(anti-neutrophil cytoplasmic antibody-associated)—rituximab
(with glucocorticoids): evaluation report. 23-7-2013.
27. Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, Cruz
D, et al. BSR and BHPR guidelines for the management of adults
with ANCA associated vasculitis. Rheumatology. 2007;46:1–11.
28. Walton E. Giant-cell granuloma of the respiratory tract (We-
gener’s granulomatosis). BMJ. 1958;2(5091):265–70.
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